Filters: keyword is Oral [Clear All Filters]
- 2008
Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats,
Br J Pharmacol, vol. 153, no. 5, pp. 1072-84.
Relevance of absorption rate and lag time to the onset of action in migraine,
Clin Pharmacokinet, vol. 47, no. 2, pp. 139-46.
- 2007
Decreased Efficacy of GABAA-receptor modulation by midazolam in the kainate model of temporal lobe epilepsy,
Epilepsia, vol. 48, no. 7, pp. 1378-87.
Application of the convection-dispersion equation to modelling oral drug absorption,
Bull Math Biol, vol. 69, no. 1, pp. 181-95.
- 1992
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers,
Clin Pharmacol Ther, vol. 51, no. 6, pp. 715-28.
- 1991
Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration,
Br J Pharmacol, vol. 102, no. 3, pp. 663-8.
The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172,
Br J Clin Pharmacol, vol. 32, no. 1, pp. 23-9.
The influence of dosage time of midazolam on its pharmacokinetics and effects in humans,
Clin Pharmacol Ther, vol. 50, no. 1, pp. 16-24.
Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers,
Eur J Clin Pharmacol, vol. 41, no. 3, pp. 245-50.
Stability and pharmacokinetics of flumazenil in the rat,
Psychopharmacology (Berl), vol. 103, no. 3, pp. 384-7.
- 1989
The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration,
Br J Clin Pharmacol, vol. 27, no. 5, pp. 581-6.
Variability in the pharmacokinetics of nisoldipine as caused by differences in liver blood flow response,
J Clin Pharmacol, vol. 29, no. 8, pp. 714-21.
Pharmacokinetics and hemodynamic effects of long-term nisoldipine treatment in hypertensive patients,
J Cardiovasc Pharmacol, vol. 13, no. 4, pp. 624-9.
- 1988
Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach,
Br J Clin Pharmacol, vol. 26, no. 4, pp. 373-84.
Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine,
Clin Pharmacol Ther, vol. 43, no. 3, pp. 332-41.
- 1987
Negligible sublingual absorption of nifedipine,
Lancet, vol. 2, no. 8572, pp. 1363-5.
- 1986
Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration,
Clin Pharmacol Ther, vol. 40, no. 1, pp. 21-8.
- 1985
Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship,
Clin Pharmacol Ther, vol. 37, no. 5, pp. 563-74.
- 1982
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time,
Eur J Clin Pharmacol, vol. 21, no. 5, pp. 433-41.
- 1979
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers,
Br J Clin Pharmacol, vol. 8, no. 6, pp. 529-37.
Assay of 3-carboxy-antipyrine in urine by capillary gas chromatography with nitrogen selective detection. Some preliminary results in man,
Pharmacology, vol. 19, no. 4, pp. 215-20.



